JP2020517645A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517645A5 JP2020517645A5 JP2019556913A JP2019556913A JP2020517645A5 JP 2020517645 A5 JP2020517645 A5 JP 2020517645A5 JP 2019556913 A JP2019556913 A JP 2019556913A JP 2019556913 A JP2019556913 A JP 2019556913A JP 2020517645 A5 JP2020517645 A5 JP 2020517645A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- oligonucleotide
- composition according
- bond
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762487425P | 2017-04-19 | 2017-04-19 | |
| US62/487,425 | 2017-04-19 | ||
| PCT/US2018/028308 WO2018195281A1 (en) | 2017-04-19 | 2018-04-19 | P-ethoxy nucleic acids for igf-1r inhibition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020517645A JP2020517645A (ja) | 2020-06-18 |
| JP2020517645A5 true JP2020517645A5 (OSRAM) | 2021-05-27 |
Family
ID=63856055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556913A Pending JP2020517645A (ja) | 2017-04-19 | 2018-04-19 | Ｉｇｆ−１ｒ阻害のためのｐ−エトキシ核酸 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20200038429A1 (OSRAM) |
| EP (1) | EP3628003A4 (OSRAM) |
| JP (1) | JP2020517645A (OSRAM) |
| KR (1) | KR20200021453A (OSRAM) |
| CN (1) | CN111447922A (OSRAM) |
| AU (1) | AU2018254485B2 (OSRAM) |
| CA (1) | CA3060090A1 (OSRAM) |
| MX (1) | MX2019012493A (OSRAM) |
| WO (1) | WO2018195281A1 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016164916A1 (en) | 2015-04-10 | 2016-10-13 | Thomas Jefferson University | Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes |
| SG11201802718PA (en) | 2015-10-14 | 2018-05-30 | Bio Path Holdings Inc | P-ethoxy nucleic acids for liposomal formulation |
| CN109963571A (zh) | 2016-09-16 | 2019-07-02 | 拜奥-帕斯控股股份有限公司 | 含有脂质体反义寡核苷酸的组合疗法 |
| EA201992490A1 (ru) | 2017-04-19 | 2020-03-03 | Байо-Пат Холдингз, Инк. | Р-этокси нуклеиновые кислоты для ингибирования bcl2 |
| AU2018255352B2 (en) | 2017-04-19 | 2023-11-16 | Bio-Path Holdings, Inc. | P-ethoxy nucleic acids for STAT3 inhibition |
| CA3118427A1 (en) * | 2018-11-02 | 2020-05-07 | Thomas Jefferson University | Methods and compositions for treating breast cancer using antisense |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6340674B1 (en) | 1993-03-26 | 2002-01-22 | Thomas Jefferson University | Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides |
| US6015886A (en) * | 1993-05-24 | 2000-01-18 | Chemgenes Corporation | Oligonucleotide phosphate esters |
| US5855911A (en) * | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
| US7704962B1 (en) * | 1997-10-03 | 2010-04-27 | Board Of Regents, The University Of Texas System | Small oligonucleotides with anti-tumor activity |
| US20030180789A1 (en) * | 1998-12-30 | 2003-09-25 | Dale Roderic M.K. | Arrays with modified oligonucleotide and polynucleotide compositions |
| AU2003207708A1 (en) * | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| US9150605B2 (en) * | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
| JP6637957B2 (ja) | 2014-07-17 | 2020-01-29 | シグニファイ ホールディング ビー ヴィＳｉｇｎｉｆｙ Ｈｏｌｄｉｎｇ Ｂ．Ｖ． | 栽培用照明装置 |
| WO2016164916A1 (en) * | 2015-04-10 | 2016-10-13 | Thomas Jefferson University | Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes |
| SG11201802718PA (en) * | 2015-10-14 | 2018-05-30 | Bio Path Holdings Inc | P-ethoxy nucleic acids for liposomal formulation |
-
2018
- 2018-04-19 CA CA3060090A patent/CA3060090A1/en active Pending
- 2018-04-19 KR KR1020197034170A patent/KR20200021453A/ko not_active Ceased
- 2018-04-19 EP EP18788289.9A patent/EP3628003A4/en not_active Withdrawn
- 2018-04-19 MX MX2019012493A patent/MX2019012493A/es unknown
- 2018-04-19 CN CN201880036079.XA patent/CN111447922A/zh active Pending
- 2018-04-19 WO PCT/US2018/028308 patent/WO2018195281A1/en not_active Ceased
- 2018-04-19 JP JP2019556913A patent/JP2020517645A/ja active Pending
- 2018-04-19 AU AU2018254485A patent/AU2018254485B2/en active Active
- 2018-04-19 US US16/606,377 patent/US20200038429A1/en not_active Abandoned
-
2021
- 2021-11-18 US US17/530,051 patent/US12472199B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gissot et al. | Nucleoside, nucleotide and oligonucleotide based amphiphiles: a successful marriage of nucleic acids with lipids | |
| Yin et al. | RNA micelles for the systemic delivery of anti-miRNA for cancer targeting and inhibition without ligand | |
| ES2924806T3 (es) | Análogos de 4'-fosfato y oligonucleótidos que comprenden el mismo | |
| CN104244928B (zh) | 磁性纳米颗粒-SAMiRNA复合物及其制备方法 | |
| JP2020517632A5 (OSRAM) | ||
| Vandghanooni et al. | Bispecific therapeutic aptamers for targeted therapy of cancer: a review on cellular perspective | |
| CN105939699A (zh) | 脂质体颗粒、制备所述脂质体颗粒的方法以及其用途 | |
| WO2010040091A1 (en) | Novel dna nanostructures that promote cell-cell interaction and use thereof | |
| Behbahani et al. | The role of exosomes contents on genetic and epigenetic alterations of recipient cancer cells | |
| Nam et al. | Size-controlled synthesis of polymerized DNA nanoparticles for targeted anticancer drug delivery | |
| CN105705638A (zh) | 改善的具有高效能的纳米颗粒型寡核苷酸结构及其制备方法 | |
| US20200405649A1 (en) | Dna origami nanoparticle delivery of programmed chromosome breakage machinery | |
| CN105051205A (zh) | 鉴定生物标记物、治疗靶点或治疗试剂的高通量筛选方法 | |
| JP2018534361A5 (OSRAM) | ||
| CN102458379B (zh) | 基于官能两亲分子或大分子的具有多隔室的配制剂 | |
| Han et al. | DNA as highly biocompatible carriers for drug delivery | |
| JP2020517646A5 (OSRAM) | ||
| Senanayake et al. | Novel anticancer polymeric conjugates of activated nucleoside analogues | |
| Mahdieh et al. | Novel polyurethane-based ionene nanoparticles electrostatically stabilized with hyaluronic acid for effective gene therapy | |
| Tan et al. | Designer tridentate mucin 1 aptamer for targeted drug delivery | |
| KR20170054429A (ko) | 치료용 나노입자 및 관련 조성물, 방법, 및 시스템 | |
| CN105779458B (zh) | 对非小细胞肺癌具有抑制作用的核糖核酸适配体及包含其的药物组合物 | |
| Xu et al. | Exosomal noncoding RNAs in gynecological cancers: implications for therapy resistance and biomarkers | |
| JP2024508119A (ja) | Ｒｎａｉコンジュゲートおよびその使用 | |
| TWI589307B (zh) | Novel manufacturing method for local administration of lipid complex and antitumor agent using the lipid complex |